Amlodipine/indapamide/telmisartan - George Medicines
Alternative Names: GMRx2; Indapamide/amlodipine/telmisartan - George Medicines; Telmisartan/amlodipine/indapamide - George MedicinesLatest Information Update: 06 May 2024
At a glance
- Originator George Medicines
- Class Antihypertensives; Benzimidazoles; Benzoates; Dihydropyridines; Indoles; Ischaemic heart disorder therapies; Small molecules; Sulfonamides
- Mechanism of Action ACE inhibitors; Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Thiazide-like diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Hypertension
Most Recent Events
- 29 Apr 2024 George Medicines plans to submit a New Drug Application (NDA) for amlodipine/indapamide/telmisartan for Hypertension, later in 2024
- 18 Oct 2023 George Medicines completes the phase III GMRx2_PCT trial in Hypertension in USA, Australia, Nigeria, Sri Lanka, and United Kingdom (NCT04518306)
- 01 Sep 2023 George Medicines completes a phase III trial in Hypertension in Australia, Czech Republic, New Zealand, Poland, Sri Lanka, United Kingdom, and in the US (PO) (NCT04518293)